Your browser doesn't support javascript.
loading
Efficacy of treatment patterns based on concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma.
Pan, Xin-Bin; Lu, Yan; Wei, You-Sheng; Yao, De-Sheng.
Affiliation
  • Pan XB; Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, 530021, Nanning, Guangxi, P.R. China.
  • Lu Y; Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, 530021, Nanning, Guangxi, P.R. China.
  • Wei YS; Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, 530021, Nanning, Guangxi, P.R. China.
  • Yao DS; Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, 530021, Nanning, Guangxi, P.R. China. yaodesheng@aliyun.com.
BMC Cancer ; 24(1): 106, 2024 Jan 18.
Article in En | MEDLINE | ID: mdl-38238689
ABSTRACT

PURPOSE:

To assess survival of treatment patterns based on concurrent chemoradiotherapy (CCRT) in patients with stage IIB cervical squamous cell carcinoma (CSCC). MATERIALS AND

METHODS:

Patients with stage IIB CSCC receiving CCRT were investigated from June 2012 to June 2019 in Guangxi Medical University Cancer Hospital. Baseline characteristics and treatment patterns were described. Survival between treatment patterns were compared using Kaplan-Meier methods.

RESULTS:

A total of 232 patients were included 39.7% of patients received CCRT alone, 6.5% of patients received neoadjuvant chemotherapy (NACT) + CCRT, 45.6% of patients received CCRT + adjuvant chemotherapy (AC), and 8.2% of patients received NACT + CCRT + AC. CCRT + AC showed similar overall survival (OS; hazard ratio [HR] = 0.95, 95% confidence interval [CI] 0.41-2.17; P = 0.894) and locoregional-free survival (LRFS; HR = 2.39, 95% CI 0.45-12.63; P = 0.303) compared with CCRT. However, CCRT + AC had a worse distant metastasis-free survival (DMFS; HR = 5.39, 95% CI 1.14-25.57; P = 0.034). After propensity score matching, CCRT + AC had comparable OS (HR = 0.89, 95% CI 0.29-2.70; P = 0.833), LRFS (HR = 3.26, 95% CI 0.30-35.38; P = 0.331), and DMFS (HR = 4.80, 95% CI 0.55-42.26; P = 0.157) compared to CCRT.

CONCLUSION:

AC did not improve survival in patients with stage IIB CSCC receiving CCRT.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Uterine Cervical Neoplasms / Nasopharyngeal Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans Country/Region as subject: Asia Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Uterine Cervical Neoplasms / Nasopharyngeal Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans Country/Region as subject: Asia Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2024 Document type: Article
...